Rate Video

ASH 2022 | Looking forward to the latest in CAR-T therapy at ASH 2022

Marion Subklewe • 29 Oct 2022

ASH 2022 COSTEM 2022

Diffuse Large B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma CAR-T

Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, highlights what she is looking forward to at ASH 2022, including the latest research on hematotoxicity in patients receiving CAR-T therapy. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Looking forward to ISAL 2023

Marion Subklewe • 12 Dec 2022

An update on AMG 330: can BiTEs be as successful in AML as ALL?

Marion Subklewe • 2 Dec 2018

Managing hematologic toxicity associated with CAR-T therapy & insights into the CAR-HEMATOTOX score

Marion Subklewe • 10 Feb 2023

Bunctional PD-1 x αCD3 x αCD33 CiTE for AML

Marion Subklewe

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

A.R.R.O.W. study: carfilzomib dosing in frail MM patients

Maria-Victoria Mateos

CAR T-cell therapy: the importance of LTFU

CD19 CAR T-cell therapy for lymphoma

Michael Schmitt